Alex­ion joins the R&D re­or­ga­ni­za­tion gala, prun­ing a slate of projects and revving up new deals

Alex­ion CEO Lud­wig Hantson is pulling the trig­ger on a pipeline re­or­ga­ni­za­tion, join­ing a mid-year gala of re­struc­tur­ings led by new CEOs at Glax­o­SmithK­line, Eli Lil­ly and Bio­gen.

In the re­vamp the biotech will now drop ALXN1101 (cPMP re­place­ment ther­a­py) and ALXN6000 (samal­izum­ab), look­ing for buy­ers to pick these ther­a­pies up. And it is punt­ing an am­bi­tious ef­fort on a range of pre­clin­i­cal pacts with Mod­er­na, Blue­print and Ar­bu­tus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER